Skip to main navigation Skip to search Skip to main content

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients with High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial

  • Dickran Kazandjian
  • , Elizabeth Hill
  • , Alexander Dew
  • , Candis Morrison
  • , Joseph Roswarski
  • , Neha Korde
  • , Michael Emanuel
  • , Ani Petrosyan
  • , Manisha Bhutani
  • , Katherine R. Calvo
  • , Alina Dulau-Florea
  • , Mary Kwok
  • , Min Jung Lee
  • , Sunmin Lee
  • , Liza Lindenberg
  • , Sham Mailankody
  • , Elisabet Manasanch
  • , Irina Maric
  • , Esther Mena
  • , Nisha Patel
    • Nishant Tageja, Jane B. Trepel, Baris Turkbey, Hao Wei Wang, Weixin Wang, Constance Yuan, Yong Zhang, Raul Braylan, Peter Choyke, Maryalice Stetler-Stevenson, Seth M. Steinberg, William D. Figg, Mark Roschewski, Ola Landgren

Research output: Contribution to journal › Article › peer-review

39   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients with High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology